CN110547415A - Undaria pinnatifida buccal tablets and preparation method and application thereof - Google Patents
Undaria pinnatifida buccal tablets and preparation method and application thereof Download PDFInfo
- Publication number
- CN110547415A CN110547415A CN201910943419.3A CN201910943419A CN110547415A CN 110547415 A CN110547415 A CN 110547415A CN 201910943419 A CN201910943419 A CN 201910943419A CN 110547415 A CN110547415 A CN 110547415A
- Authority
- CN
- China
- Prior art keywords
- filtrate
- undaria pinnatifida
- centrifugal separation
- buccal tablet
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001261506 Undaria pinnatifida Species 0.000 title claims abstract description 50
- 239000006189 buccal tablet Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000000706 filtrate Substances 0.000 claims abstract description 49
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 33
- 238000000926 separation method Methods 0.000 claims abstract description 29
- 239000000843 powder Substances 0.000 claims abstract description 25
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract description 22
- 108091005804 Peptidases Proteins 0.000 claims abstract description 21
- 239000004365 Protease Substances 0.000 claims abstract description 21
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 21
- 229940046011 buccal tablet Drugs 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 17
- 238000010438 heat treatment Methods 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 11
- 229930006000 Sucrose Natural products 0.000 claims abstract description 11
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims abstract description 11
- 239000007853 buffer solution Substances 0.000 claims abstract description 11
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 11
- 239000005720 sucrose Substances 0.000 claims abstract description 11
- 102000004190 Enzymes Human genes 0.000 claims abstract description 10
- 108090000790 Enzymes Proteins 0.000 claims abstract description 10
- 230000009849 deactivation Effects 0.000 claims abstract description 10
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 229940088598 enzyme Drugs 0.000 claims description 9
- 108091005658 Basic proteases Proteins 0.000 claims description 5
- 102000057297 Pepsin A Human genes 0.000 claims description 5
- 108090000284 Pepsin A Proteins 0.000 claims description 5
- 102000004142 Trypsin Human genes 0.000 claims description 5
- 108090000631 Trypsin Proteins 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 229940111202 pepsin Drugs 0.000 claims description 5
- 239000012588 trypsin Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 235000020510 functional beverage Nutrition 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 241001474374 Blennius Species 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 108090000623 proteins and genes Proteins 0.000 abstract description 9
- 238000000605 extraction Methods 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 5
- 229920001184 polypeptide Polymers 0.000 abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 description 1
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- -1 iodine, sterol compounds Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/60—Edible seaweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/65—Addition of, or treatment with, microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
- A23L2/395—Dry compositions in a particular shape or form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Health & Medical Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to an undaria pinnatifida buccal tablet and a preparation method and application thereof, wherein the method comprises the following steps: preparing undaria pinnatifida into powder, mixing the powder with water, heating, carrying out centrifugal separation to obtain a first filtrate, adding a phosphoric acid buffer solution, stirring, adding protease for enzymolysis, carrying out enzyme deactivation treatment, and carrying out centrifugal separation to obtain a second filtrate; adding sucrose, citric acid and skimmed milk powder into the second filtrate, blending, and tabletting to obtain thallus laminariae buccal tablet. The preparation method of the undaria pinnatifida buccal tablets improves the extraction rate and the enzymolysis rate of the undaria pinnatifida protein, the extraction rate of the undaria pinnatifida protein reaches 88.24%, and the polypeptide with a certain sobering function is finally obtained by optimizing the enzymolysis process, so that the utilization rate of the undaria pinnatifida is greatly improved.
Description
Technical Field
The invention belongs to the technical field of beverages, and particularly relates to an undaria pinnatifida buccal tablet as well as a preparation method and application thereof.
Background
Undaria pinnatifida has high economic value and medicinal value, not only contains rich proteins, vitamins and minerals, but also contains a plurality of active ingredients with unique physiological functions, such as alginic acid, mannitol, fucoidan, high unsaturated fatty acid, fucoxanthin, organic iodine, sterol compounds, dietary fibers and the like. Has multiple pharmacological actions such as reducing blood fat, reducing blood pressure, regulating immunity, resisting mutation, resisting tumor, etc., and has good effects in resisting virus, resisting tumor, reducing blood pressure, reducing weight, treating cardiovascular and cerebrovascular diseases, etc. The undaria pinnatifida contains eight amino acids which are necessary for human bodies and are excellent protein sources, but the undaria pinnatifida has serious waste of protein resources and low utilization rate in the processing process at present.
Disclosure of Invention
The invention aims to provide a preparation method of an undaria pinnatifida buccal tablet.
The preparation method of the undaria pinnatifida buccal tablets comprises the following steps: s101: firstly, cleaning undaria pinnatifida with clear water, drying and crushing the undaria pinnatifida into powder; s102: mixing the powder with water according to a material-liquid ratio of 1 g: (10 mL-30 mL), adjusting the pH value to 7.0-9.0, heating and then performing centrifugal separation to obtain a first filtrate; s103: adding a phosphoric acid buffer solution into the first filtrate, stirring, adding protease for enzymolysis, performing enzyme deactivation treatment, and performing centrifugal separation to obtain a second filtrate; wherein the volume ratio of the first filtrate to the phosphoric acid buffer solution is 5: (1-3), wherein the volume of the first filtrate and the mass of the protease are 5 mL: (1 mg-3 mg); s104: adding sucrose, citric acid and skimmed milk powder into the second filtrate for blending, and tabletting to obtain thallus laminariae buccal tablet; wherein the sucrose accounts for 1-5% of the mass of the second filtrate, the citric acid accounts for 0.1-1% of the mass of the second filtrate, the skimmed milk powder accounts for 40-60% of the mass of the second filtrate, and the vegetable and fruit juice accounts for 30-50% of the mass of the second filtrate.
The preparation method of the undaria pinnatifida buccal tablets improves the extraction rate and the enzymolysis rate of the undaria pinnatifida protein, the extraction rate of the undaria pinnatifida protein reaches 88.24%, and the polypeptide with a certain sobering function is finally obtained by optimizing the enzymolysis process, so that the utilization rate of the undaria pinnatifida is greatly improved. The undaria pinnatifida buccal tablets prepared by the method have the effects of reducing blood fat, reducing blood pressure, regulating immunity, resisting mutation, resisting tumor and the like, have good pharmacological action in the aspects of resisting virus, resisting tumor, reducing blood pressure, losing weight, treating cardiovascular and cerebrovascular diseases and the like, and have good commercial prospect.
In addition, the preparation method of the undaria pinnatifida buccal tablet can also have the following additional technical characteristics:
Further, in the step S103, the protease is a complex protease, an alkaline protease, pepsin and trypsin at a weight ratio of 1: (0.8-1.2): (0.8-1.2): (0.8-1.2) mixing.
Further, in the step S102, the rotation speed of centrifugal separation is 5000r/min to 7000r/min, and the time of centrifugal separation is 10min to 15 min.
further, in the step S103, the rotation speed of centrifugal separation is 4000r/min to 6000r/min, and the time of centrifugal separation is 8min to 12 min.
Further, in the step S101, the particle size of the powder is 50 to 500 meshes.
Further, in the step S102, the heating mode is water bath heating, the heating temperature is 45 ℃ to 55 ℃, and the heating time is 3h to 4 h.
Further, in the step S103, during the enzymolysis, the enzymolysis is performed for 3 to 5 hours at a temperature of 35 to 38 ℃, and then the enzymolysis is performed for 2 to 4 hours at a temperature of 48 to 52 ℃.
Further, in step S103, the specific operation of the enzyme deactivation process is: heating to 83-88 ℃ for enzyme deactivation treatment for 15-18 min.
The invention also aims to provide the undaria pinnatifida buccal tablets prepared by the method.
The invention also aims to provide the application of the undaria pinnatifida buccal tablets in preparing functional beverages, foods and health-care products.
additional aspects and advantages of the invention will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the invention.
Detailed Description
The following detailed description of embodiments of the invention is intended to be illustrative, and not to be construed as limiting the invention.
Example 1
Example 1 provides an undaria pinnatifida buccal tablet, and the preparation method thereof comprises the following steps:
(1) Firstly, the undaria pinnatifida is cleaned by clear water, and then the undaria pinnatifida is dried and crushed into powder with the grain diameter of 50 meshes.
(2) Mixing the powder with water according to a material-liquid ratio of 1 g: after 30mL of the mixture was mixed, the pH was adjusted to 7.0, and the mixture was heated in a water bath at 55 ℃ for 3 hours and then centrifuged to obtain a first filtrate. Wherein the rotation speed of centrifugal separation is 7000r/min, and the time of centrifugal separation is 10 min.
(3) Adding a phosphoric acid buffer solution into the first filtrate, stirring, adding protease, performing enzymolysis at 38 ℃ for 3h, performing enzymolysis at 52 ℃ for 4h, heating to 88 ℃ after enzymolysis, performing enzyme deactivation treatment for 15min, and performing centrifugal separation to obtain a second filtrate; wherein the volume ratio of the first filtrate to the phosphoric acid buffer solution is 5: 3, the volume of the first filtrate and the mass of the protease are 5 mL: 1 mg; the rotation speed of the centrifugal separation is 6000r/min, and the time of the centrifugal separation is 8 min. The protease is compound protease, alkaline protease, pepsin and trypsin according to the weight ratio of 1: 1.2: 0.8: 1.2 mixing.
(4) adding sucrose, citric acid and skimmed milk powder into the second filtrate for blending, and tabletting to obtain thallus laminariae buccal tablet; wherein the sucrose accounts for 1% of the mass of the second filtrate, the citric acid accounts for 1% of the mass of the second filtrate, and the skimmed milk powder accounts for 40% of the mass of the second filtrate.
Example 2
Embodiment 2 provides an undaria pinnatifida buccal tablet, and the preparation method thereof comprises the following steps:
(1) firstly, the undaria pinnatifida is cleaned by clear water, and then the undaria pinnatifida is dried and crushed into powder with the particle size of 500 meshes.
(2) Mixing the powder with water according to a material-liquid ratio of 1 g: after 10mL of the mixture was mixed, the pH was adjusted to 9.0, and the mixture was heated in a water bath at 45 ℃ for 4 hours and centrifuged to obtain a first filtrate. Wherein the rotation speed of the centrifugal separation is 5000r/min, and the time of the centrifugal separation is 15 min.
(3) Adding a phosphoric acid buffer solution into the first filtrate, stirring, adding protease, performing enzymolysis at 35 ℃ for 5 hours, performing enzymolysis at 48 ℃ for 2 hours, heating to 83 ℃ after enzymolysis, performing enzyme deactivation treatment for 18min, and performing centrifugal separation to obtain a second filtrate; wherein the volume ratio of the first filtrate to the phosphoric acid buffer solution is 5: 1, the volume of the first filtrate and the mass of the protease are 5 mL: 3 mg; the rotation speed of the centrifugal separation is 4000r/min, and the time of the centrifugal separation is 12 min. The protease is compound protease, alkaline protease, pepsin and trypsin according to the weight ratio of 1: 0.8: 1.2: 0.8 mixing.
(4) Adding sucrose, citric acid and skimmed milk powder into the second filtrate for blending, and tabletting to obtain thallus laminariae buccal tablet; wherein the sucrose accounts for 5% of the mass of the second filtrate, the citric acid accounts for 0.1% of the mass of the second filtrate, and the skimmed milk powder accounts for 60% of the mass of the second filtrate.
Example 3
embodiment 3 provides an undaria pinnatifida buccal tablet, and the preparation method thereof comprises the following steps:
(1) Firstly, the undaria pinnatifida is cleaned by clear water, and then the undaria pinnatifida is dried and crushed into powder with the grain diameter of 250 meshes.
(2) Mixing the powder with water according to a material-liquid ratio of 1 g: after 20mL of the mixture was mixed, the pH was adjusted to 8.0, and the mixture was heated in a water bath at 50 ℃ for 3.5 hours and centrifuged to obtain a first filtrate. Wherein the rotation speed of the centrifugal separation is 6000r/min, and the time of the centrifugal separation is 13 min.
(3) Adding a phosphoric acid buffer solution into the first filtrate, stirring, adding protease, performing enzymolysis at 36 ℃ for 4h, performing enzymolysis at 50 ℃ for 3h, heating to 85 ℃ after enzymolysis, performing enzyme deactivation treatment for 17min, and performing centrifugal separation to obtain a second filtrate; wherein the volume ratio of the first filtrate to the phosphoric acid buffer solution is 5: 2, the volume of the first filtrate and the mass of the protease are 5 mL: 2 mg; the rotation speed of the centrifugal separation is 5000r/min, and the time of the centrifugal separation is 10 min. The protease is compound protease, alkaline protease, pepsin and trypsin according to the weight ratio of 1: 1: 1: 1 and mixing.
(4) Adding sucrose, citric acid and skimmed milk powder into the second filtrate for blending, and tabletting to obtain thallus laminariae buccal tablet; wherein the sucrose accounts for 3% of the mass of the second filtrate, the citric acid accounts for 0.5% of the mass of the second filtrate, and the skimmed milk powder accounts for 50% of the mass of the second filtrate.
In conclusion, the preparation method of the undaria pinnatifida buccal tablets improves the extraction rate and the enzymolysis rate of the undaria pinnatifida protein, the extraction rate of the undaria pinnatifida protein reaches 88.24%, the polypeptide with a certain sobering function is finally obtained by optimizing the enzymolysis process, and the utilization rate of the undaria pinnatifida is greatly improved. The undaria pinnatifida buccal tablets prepared by the method have the effects of reducing blood fat, reducing blood pressure, regulating immunity, resisting mutation, resisting tumor and the like, have good pharmacological action in the aspects of resisting virus, resisting tumor, reducing blood pressure, losing weight, treating cardiovascular and cerebrovascular diseases and the like, and have good commercial prospect.
in the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples and features of different embodiments or examples described in this specification can be combined and combined by one skilled in the art without contradiction.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.
Claims (10)
1. A preparation method of the undaria pinnatifida buccal tablets is characterized by comprising the following steps:
S101: firstly, cleaning undaria pinnatifida with clear water, drying and crushing the undaria pinnatifida into powder;
s102: mixing the powder with water according to a material-liquid ratio of 1 g: (10 mL-30 mL), adjusting the pH value to 7.0-9.0, heating and then performing centrifugal separation to obtain a first filtrate;
S103: adding a phosphoric acid buffer solution into the first filtrate, stirring, adding protease for enzymolysis, performing enzyme deactivation treatment, and performing centrifugal separation to obtain a second filtrate; wherein the volume ratio of the first filtrate to the phosphoric acid buffer solution is 5: (1-3), wherein the volume of the first filtrate and the mass of the protease are 5 mL: (1 mg-3 mg);
S104: adding sucrose, citric acid and skimmed milk powder into the second filtrate for blending, and tabletting to obtain thallus laminariae buccal tablet; wherein the sucrose accounts for 1-5% of the mass of the second filtrate, the citric acid accounts for 0.1-1% of the mass of the second filtrate, and the skimmed milk powder accounts for 40-60% of the mass of the second filtrate.
2. The method for preparing the undaria pinnatifida buccal tablets according to claim 1, wherein in the step S103, the protease is complex protease, alkaline protease, pepsin and trypsin in a weight ratio of 1: (0.8-1.2): (0.8-1.2): (0.8-1.2) mixing.
3. The method for preparing the wakame seaweed buccal tablet as claimed in claim 1, wherein in the step S102, the rotational speed of centrifugal separation is 5000r/min to 7000r/min, and the time of centrifugal separation is 10min to 15 min.
4. The preparation method of the wakame seaweed buccal tablet as claimed in claim 1, wherein in the step S103, the rotational speed of centrifugal separation is 4000r/min to 6000r/min, and the time of centrifugal separation is 8min to 12 min.
5. The method for preparing the wakame seaweed buccal tablet as claimed in claim 1, wherein in the step S101, the particle size of the powder is 50 to 500 meshes.
6. The preparation method of the undaria pinnatifida buccal tablet according to claim 1, wherein in the step S102, the heating mode is water bath heating, the heating temperature is 45-55 ℃, and the heating time is 3-4 h.
7. The preparation method of the undaria pinnatifida buccal tablet according to claim 1, wherein in the step S103, enzymolysis is performed at 35-38 ℃ for 3-5 h, and then at 48-52 ℃ for 2-4 h.
8. the method for preparing the wakame seaweed buccal tablet as claimed in claim 1, wherein in the step S103, the specific operation of the enzyme deactivation treatment is as follows: heating to 83-88 ℃ for enzyme deactivation treatment for 15-18 min.
9. A buccal tablet of undaria pinnatifida prepared by the method of any one of claims 1 to 8.
10. The use of the undaria pinnatifida buccal tablet of claim 9 in the preparation of functional beverages, foods and health products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910943419.3A CN110547415A (en) | 2019-09-30 | 2019-09-30 | Undaria pinnatifida buccal tablets and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910943419.3A CN110547415A (en) | 2019-09-30 | 2019-09-30 | Undaria pinnatifida buccal tablets and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110547415A true CN110547415A (en) | 2019-12-10 |
Family
ID=68742172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910943419.3A Pending CN110547415A (en) | 2019-09-30 | 2019-09-30 | Undaria pinnatifida buccal tablets and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110547415A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112301082A (en) * | 2020-11-03 | 2021-02-02 | 鲁东大学 | Undaria pinnatifida antitumor small molecular peptide and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003000153A (en) * | 2001-06-22 | 2003-01-07 | Suetsuna Yoko | Enzymic hydrolyzate of undaria pinnatifida and use thereof |
| JP2004097021A (en) * | 2002-09-05 | 2004-04-02 | Shirako:Kk | Wakame protein-containing composition, and wakame protein-containing food |
| CN1528185A (en) * | 2003-09-27 | 2004-09-15 | 张立一 | Undaria Plnnatifida slice and making method thereof |
| CN106119327A (en) * | 2016-06-29 | 2016-11-16 | 大连深蓝肽科技研发有限公司 | The method that oligopeptide makes the oligomeric Gly-His-Lys of Sargassum is extracted from Sargassum |
-
2019
- 2019-09-30 CN CN201910943419.3A patent/CN110547415A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003000153A (en) * | 2001-06-22 | 2003-01-07 | Suetsuna Yoko | Enzymic hydrolyzate of undaria pinnatifida and use thereof |
| JP2004097021A (en) * | 2002-09-05 | 2004-04-02 | Shirako:Kk | Wakame protein-containing composition, and wakame protein-containing food |
| CN1528185A (en) * | 2003-09-27 | 2004-09-15 | 张立一 | Undaria Plnnatifida slice and making method thereof |
| CN106119327A (en) * | 2016-06-29 | 2016-11-16 | 大连深蓝肽科技研发有限公司 | The method that oligopeptide makes the oligomeric Gly-His-Lys of Sargassum is extracted from Sargassum |
Non-Patent Citations (1)
| Title |
|---|
| 于慧等: ""响应面试验优化裙带菜蛋白酶解工艺及酶解液抗氧化活性"", 《食品科学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112301082A (en) * | 2020-11-03 | 2021-02-02 | 鲁东大学 | Undaria pinnatifida antitumor small molecular peptide and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106282287B (en) | Method for extracting bioactive polypeptide of ginkgo | |
| CN103005591B (en) | Ginkgo and wheat germ beverage and preparation method thereof | |
| CN104095243A (en) | Preparation technology for enzymolysis bioactive peptide nanometer selenium | |
| CN101496581B (en) | Health-care food for adjusting blood fat | |
| CN103859368A (en) | Sea cucumber beverage and production method thereof | |
| CN108851045A (en) | A kind of pectase and preparation method thereof | |
| CN105639560A (en) | Biological-enzymolysis-method sporoderm-broken lucid ganoderma spore powder honey for calming nerves and aiding sleep and production process thereof | |
| CN111329055B (en) | Preparation method of trifoliate acanthopanax enzyme | |
| KR101184962B1 (en) | Pancakes manufacturing method which uses the seaweeds and sea tangle | |
| CN103301321B (en) | Thrombolytic active polysaccharide mixture preparation technology | |
| CN110547415A (en) | Undaria pinnatifida buccal tablets and preparation method and application thereof | |
| CN112370516A (en) | A wall-broken Ganoderma spore powder product with active ingredients and its preparation method | |
| CN101654641A (en) | Fig wine and production process thereof | |
| CN103598593A (en) | Manufacturing method of sea cucumber nutrient tablets | |
| CN110169485A (en) | A kind of red yeast rice natto pressed candy and preparation method thereof | |
| CN105249094A (en) | Lactation promoting pure natural cereal drink and material mixing structure | |
| CN104739916A (en) | Alpha-glucosidase active inhibitor as well as preparation method and application thereof | |
| CN112293746B (en) | Walnut protein polysaccharide compound oil gel | |
| CN109810830A (en) | A kind of bitter buckwheat highland barley wine starter and preparation method thereof | |
| CN106509555A (en) | Rice milk beverage and preparation method thereof | |
| CN106387897A (en) | Preparation method of Luohanshen ferment stock solution | |
| CN105441266B (en) | A kind of red hayberry wine and preparation method thereof | |
| CN111280452A (en) | Novel natto polypeptide health food | |
| CN103599468A (en) | Manufacturing method of sea cucumber tablet for adjusting immunity | |
| CN107865272A (en) | A kind of preparation method of cough-relieving Chinese Drug Gualouzi beverage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191210 |